Fiona C. Baker, PhD

Fiona C. Baker, PhD, compares elinzanetant with current therapeutic options, noting how its profile aligns with the needs of patients experiencing both VMS and sleep disturbances.

Fiona C. Baker, PhD, emphasizes the importance of patient-reported outcomes in assessing elinzanetant’s overall benefit, including insights on symptom recurrence and quality-of-life improvements.

Fiona C. Baker, PhD, reviews NIRVANA’s findings showing early onset of relief for both VMS and sleep disturbances, supported by patient-reported improvements in sleep quality, duration, and nighttime awakenings.

Fiona C. Baker, PhD, outlines the NIRVANA study’s design and goals, noting its focus on evaluating elinzanetant’s impact on vasomotor symptoms and sleep-related outcomes.